Navigation Links
Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring?
Date:8/13/2008

PORTLAND, Ore., Aug. 13 /PRNewswire/ -- Today positron emission tomography (PET) scanning is emerging as an increasingly helpful oncology tool for diagnosis, staging and monitoring. It is a computer-based, low-resolution imaging technology emitting a radioactive tracer to localize tumors. The radioactive positron tracer gathers in abnormal tissue. As a result, the malignant tissue stands out from normal tissue and appears as a "hot spot."

The use of multiple imaging technologies is growing in importance for the diagnosis, staging and monitoring treatment for many types of cancers. Once an oncologist diagnoses a patient with cancer, current standards of care require the doctor to decide which stage a cancer patient has reached. Before completing a treatment plan, the oncologist must decide whether the malignancy is localized, attacking nearby tissues or spreading to other parts of the body.

"After the staging step, oncologists often monitor a patient's cancer treatment for effectiveness or reappearance of a tumor," said Dr. Skip Freedman, executive medical director at AllMed Healthcare Management, a leading Independent Review Organization (IRO). http://www.allmedmd.com

According to Freedman, an oncologist usually combines a PET scan with computed tomography (CT) to capture higher resolution pictures of a patient's tissue. Because the PET images are low-resolution, oncologists combine the two to increase the image resolution and clarity of any "hot spots" showing up in the PET scan.

However, scanning is expensive, about $1,800 for PET and $2,100 for a combined PET and CT scan. Both also emit high doses of radiation, about 150 chest x-ray equivalents (CXREs) for a PET scan and 350 to 550 CXREs for combined PET and CT scans. One CXRE equals the radiation a patient receives from one X-ray. So there are tradeoffs for both doctors and patients to consider.

"For many tumors, PET scans are only a slightly more effective diagnostic tool in terms of sensitivity and specificity than CT scans or MRIs," said Freedman. "So their use is being researched to discover if and how much they may improve patient outcomes."

The Center for Medicare and Medicaid Services is one agency currently studying how PET scans might change oncology treatment decisions and improve patient outcomes. The agency currently approves PET scans for several types of cancer including colorectal, lymphoma, head and neck, pancreatic, testicular and several others.

For more information on leading-edge treatments and their medical necessity, check out http://www.allmedmd.com/peerpoints/cuttingedge/cutting_edge_email.htm. Or view AllMed's Webinar, "Cancer Testing and Treatment: New Questions, New Answers" at http://www.allmedmd.com/resources/downloads/webinar4_download.html (requires registration). To find out more about the medical review services that IROs offer, go to AllMed's Website at http://www.allmedmd.com.


'/>"/>
SOURCE AllMed Healthcare Management
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PET Scans Show Gene Therapy Normalizes Brain Function in Parkinsons Patients
2. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
3. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
7. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
10. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
11. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):